Clinical trial NCT01792986: The Fasting II Study
Official title: Preparatory Study to Determine Which Risk Markers May be Reduced by Fasting and Should be Evaluated in a Future Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Metabolic Diseases
Keywords: Diabetes
Fasting
Pre-diabetes
Hemoglobin A1C
Lead sponsor: Intermountain Health Care, Inc.
Sponsor class: OTHER
Collaborators: name: Intermountain Research and Medical Foundation
First posted: 2013-02-15
Enrollment: 12
Sex: ALL
Minimum age (years): 30
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study will determine whether an intensive fasting protocol alters hemoglobin A1c measurements or other markers of metabolic and cardiovascular risk by performing a 5-week clinical trial of fasting among 12 pre-diabetic individuals or diabetics whose disease is controlled by diet. Participants will undergo a 5-week intervention of once-per-week 24-hour water-only fasting, including at baseline and at the end of the week for each week of the study (a total of 6 24-hour fasts).


Eligibility criteria: Inclusion Criteria:

1. Male or non-pregnant female, ≥30 and \<70 years of age.
2. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.
3. Prior evidence of pre-diabetic state, with one of the following:

   1. Pre-diabetic with a measured hemoglobin A1c (HbA1c) ≥6.0% or fasting glucose \>100 mg/dL without a clinical diabetes diagnosis
   2. Clinically-diagnosed type II diabetic with HbA1c ≥6.0% or fasting glucose ≥110 mg/dL and whose disease is controlled by diet alone.
4. Evidence of metabolic syndrome by having at least 3 of the following 5 criteria:

   1. Fasting glucose level \>100 mg/dL.
   2. Blood pressure ≥135 mmHg systolic or ≥85 mmHg diastolic, or use of an antihypertensive medication.
   3. High-density lipoprotein cholesterol \<40 mg/dL in males or \<50 mg/dL in females.
   4. Triglycerides ≥150 mg/dL or use of a cholesterol-lowering medication.
   5. Waist circumference \>40 inches (102 cm) for males or \>35 inches (88 cm) for females (or body mass index \>25 kg/m2).

Exclusion Criteria:

1. Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Principal Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.
2. Diabetics taking any of the following anti-diabetic medications: insulin, metformin, thiazolidinediones, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, or incretins.
3. Prior experience with fasting more than once per month (for 20 hours or more), on average during the last year.
4. Very low body mass index (BMI) (\<18.5 kg/m2) or high BMI (\>40 kg/m2).
5. Individuals who are nutritionally compromised, as assessed by the Principal Investigator.
6. Any immunodeficiency or prior solid organ transplantation or renal disease.
7. Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
8. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

Primary outcomes:
measure: Difference in Mean Glucose Level Between Baseline and the End of the Sixth Week.
timeFrame: 6 weeks
Secondary outcomes:
measure: Difference in Weight Between Baseline and the End of the Sixth Week
timeFrame: 6 weeks
measure: Difference in Low-density Lipoprotein Cholesterol (LDL-C) Between Baseline and the End of the Sixth Week.
timeFrame: 6 weeks
measure: Difference in Human Growth Hormone (HGH) Between Baseline and the End of the Sixth Week.
timeFrame: 6 weeks
measure: Difference in Red Blood Cell Count Between Baseline and the End of the Sixth Week.
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Murray
country: United States
facility: Intermountain Medical Center
state: Utah
city: Salt Lake City
country: United States
facility: Intermountain Medical Center
state: Utah
Study officials:
affiliation: Intermountain Health Care, Inc.
name: Benjamin D Horne, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References: